Opinion|Videos|June 19, 2024
Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
- Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5